Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 2/20 | 0.59 |
| ▸ | TXNRD1 | Q16881 | 13/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | MGMT | P16455 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30112419 | 0.90 | PIN1 (0.63) | PIN1TXNRD1RAB9AMEN1NPC1 | |
| SCHEMBL20277911 | 0.84 | PIN1 (0.56) | PIN1TXNRD1RAB9AMAPTNPSR1 | |
| SCHEMBL20278132 | 0.83 | PIN1 (0.61) | PIN1RAB9AMAPTMEN1NPC1 | |
| SCHEMBL4651284 | 0.81 | PIN1 (0.69) | PIN1TXNRD1RAB9AMAPTMEN1 | |
| SCHEMBL4652383 | 0.80 | APP (0.57) | PIN1RAB9AMAPTMEN1NPC1 | |
| SCHEMBL10740434 | 0.79 | TXNRD1 (0.58) | TXNRD1RAB9AS1PR4MAPTS1PR1 | |
| SCHEMBL4652574 | 0.78 | APP (0.67) | PIN1RAB9AMEN1NPC1KMT2A | |
| SCHEMBL14332844 | 0.78 | PIN1 (0.59) | PIN1RAB9AMEN1NPC1KMT2A | |
| SCHEMBL30271339 | 0.78 | PIN1 (0.49) | PIN1TXNRD1RAB9AMEN1NPC1 | |
| SCHEMBL23273999 | 0.78 | PIN1 (0.54) | PIN1TXNRD1RAB9AMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4380560-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | Contineum Therapeutics, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| WO-2023014908-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | Pipeline Therapeutics, Inc. (US) | 2023-02-09 | — | — | WO | disclosed |
| EP-1392280-A4 | ARYLSULFONAMIDE ETHERS, AND METHODS OF USE THEREOF | WARNER LAMBERT CO (US) | 2005-11-30 | — | — | EP | disclosed |
| US-6875765-B2 | Arylsulfonamide ethers, and methods of use thereof | WARNER-LAMBERT COMPANY (US) | 2005-04-05 | — | — | US | disclosed |
| EP-1392280-A2 | ARYLSULFONAMIDE ETHERS, AND METHODS OF USE THEREOF | Abbott GmbH & Co. KG (DE) | 2004-03-03 | — | — | EP | disclosed |
| US-20030096826-A1 | Arylsulfonamide ethers, and methods of use thereof | WARNER-LAMBERT COMPANY | 2003-05-22 | — | — | US | disclosed |
| WO-2002089749-A2 | ARYLSULFONAMIDE ETHERS, AND METHODS OF USE THEREOF | ABBOTT GMBH & CO.KG (DE) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096826-A1 | Arylsulfonamide ethers, and methods of use thereof | CASP1, IRAK1, STS | PIN1 1552/4885TXNRD1 1110/4885RAB9A 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.